JPRN-UMIN000006659
Recruiting
未知
Examination of efficacy and safety of PEG-IFN alpha-2a plus Adefovir dipivoxil for the treatment of chronic hepatitis B - PEG-IFN alpha-2a plus Adefovir therapy for chronic hepatitis B
Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine0 sites50 target enrollmentJanuary 4, 2012
Conditionschronic hepatitis B
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- chronic hepatitis B
- Sponsor
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patient who is administering the sho\-sai\-ko\-to 2\. A patient with the previous history of interstitial pneumonia 3\. Other chronic liver disease patients such as autoimmune hepatitis or alcoholic hepatitis 4\. Patient who has previous history of hypersensitivity for element of PEG\-IFN alpha\-2a or other IFNs 5\. Patient who has previous history of hypersensitivity for biological products such as vaccines 6\. Patient with cirrhosis, liver failure, and liver carcinoma 7\. Hepatic encephalopathy, an esophageal varix, a patient with abdominal dropsy, or a patient with these previous history 8\. A patient with autoimmune diseases (hemolytic anemia, chronic ulcerative colitis, rheumatoid arthritis, etc.), or a patient with these anamneses 9\. Patient who has heart disease difficult to control (cardiac infarction, cardiac failure, and arrhythmia, etc.) 10\. Patient who exists in serious state of mental disease of serious depression, thought of suicide or suicide plan, etc. or with these history 11\. The patient of uncontrollable hypertension 12\. A patient with the past of apoplexy (cerebral infarction, cerebral hemorrhage, subarachnoid bleeding, transient ischemic attack) 13\. Pregnant woman or woman who has possibility of pregnancy or woman while suckling 14\. Additionally, patient judged by doctor that participation in this study is improper 15\. The patient who has the resistant to nucleic acid analog, such as Lamivudine and Entecavir
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Examination of efficacy and safety of PEG-IFN alpha-2a for the treatment of chronic hepatitis B.chronic hepatitis BJPRN-UMIN000006649Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine100
Recruiting
Not Applicable
Assessment of efficacy and safety of PEG-IFN alpha-2a administration into patients with chronic hepatitis B on nuleoside analogueChronic hepatitis BJPRN-UMIN000015633Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Defense Medical College100
Completed
Phase 4
Treatment efficacy of short-term PEG-IFN alpha for chronic hepatitis C patients with genotype 2 and low viral roadchronic hepatitis CJPRN-UMIN000001170Gunma Liver Study Group220
Completed
Not Applicable
PEG-IFN Alpha (Injection) in Chronic Hepatitis B Patients.Health Condition 1: null- Hepatitis B VirusHealth Condition 2: K768- Other specified diseases of liverCTRI/2017/07/008991Institute of liver and Biliary Sciences118
Recruiting
Phase 2
A Phase2 study of the safety and efficacy of pegfilgrastism for the prevention of febrile neutropenia in patients receiving TPF therapy for squamous cell carcinoma of the head and neck.JPRN-jRCTs031220695Saito Yuki18